News

LEO Pharma's Adbry, a single-dose autoinjector, is expected to become available to patients in the coming months.

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

To address the increased rates of skin cancer while keeping unique patient needs top of mind, there is a pressing need to increase options for treatment.

A recent review found that teledermatology could improve patient access, increase efficiency, and cut down on costly hospital admissions.

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between July and September. Share your thoughts with us by June 26.

Conversely, there were higher levels of selenium and folic acid detected in patients with vitiligo versus otherwise healthy individuals.

The study found patients with vitiligo are at a lower risk of developing PD, but those with comorbid PD could face elevated mortality rates.

Researchers hypothesize that skin contact with e-cigarette fluids can trigger an inflammatory response.

Catch up on all clinical pearls from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC, debated which patients are a contender for systemic therapy.

The data, presented at RAVE 2024, continued a positive trend, building upon strong phase 1 results of rademikibart for patients with AD.

A recent study investigated the technology as a resource for patients seeking online medical information.

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Step therapy can delay appropriate care and potentially worsen patients' conditions, writes Dermatology Times Spring Editor in Chief Aaron Farberg, MD.

Kristine Kucera, PA-C, MPAS, DHS, discusses the atopic dermatitis patient experience alongside one of her patients, Mickey Bryson.

A study out of Japan found the burden on patients with atopic dermatitis and their caregivers can increase with age and disease severity.

Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

The phase 3 IZAR program will evaluate the efficacy and safety of sonelokimab in patients with psoriatic arthritis for a 1 year duration.

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

The trial reported complete hair regrowth for a number of participants, with 76% of a partial cohort meeting the primary endpoint of 30% improvement.

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Phase 3 clinical trial results showed that the safety and tolerability profiles were consistent with those observed in the original pivotal trials.

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Catch up on coverage from the first day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.

Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.